Marshall University and the Joan C. Edwards School of Medicine announced the open recruitment of patients with stage 2 or stage 3 nonalcoholic steatohepatitis for a clinical trial designed to evaluate the safety and efficacy of the investigational drug cenicriviroc for late-stage liver disease, according to a press release.
“The most serious liver complication of obesity is nonalcoholic steatohepatitis, or NASH, which is very common in West Virginia and the Tri-State region,” Uma Sundaram, MD, vice dean for research and graduate education at the Marshall University School of Medicine and the school’s principal investigator of the trial, said in the release.
The trail is part of the ongoing phase 3 AURORA study through Allergan. Investigators will compare the effectiveness and safety profile of the investigational drug compared with placebo in adults aged 18 years to 75 years with NASH.
Other centers participating in research of cenicriviroc include the Appalachian Clinical and Translational Science Institute, the Appalachian Center for Cellular Transport in Obesity Related Disorders, the Marshall Institute for Interdisciplinary Research, and the West Virginia IDeA Network of Biomedical Research Excellence.